British journal of hospital medicine (London, England : 2005) · 2026
A Retrospective Comparative Study of Sodium Ferulate Combined With Methylcobalamin for Oxaliplatin-Induced Peripheral Neuropathy in Patients With Colorectal Cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Min Baojun, Wan Li, He Hongyong, Chen Jie, Jian Zhonglu, Chen Rong
Аннотация
AIMS/BACKGROUND: Oxaliplatin-induced peripheral neuropathy (OIPN) is a common dose-limiting toxic effect of oxaliplatin-based chemotherapy for colorectal cancer (CRC), severely affecting patients' quality of life and treatment adherence. Currently, effective therapeutic options for OIPN are limited. This study aimed to investigate the clinical efficacy and safety of sodium ferulate combined with methylcobalamin in the treatment of OIPN in CRC patients.
METHODS: In this retrospective cohort study, 280 CRC patients diagnosed with OIPN following oxaliplatin-based chemotherapy at Qianxi People's Hospital between January 2020 and December 2024 were enrolled. Based on treatment regimen, patients were assigned to an observation group (sodium ferulate combined with methylcobalamin, n = 152) or a control group (methylcobalamin alone, n = 128). All patients received basic nursing care. Treatment duration was 8 weeks for both groups. Outcomes compared between groups included National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) neurotoxicity grading, nerve conduction velocity (NCV), and quality of life (QoL) scores assessed before treatment, at 4 weeks, and at 8 weeks post-treatment. Clinical efficacy was evaluated after 8 weeks, and changes in hematological parameters and liver/kidney function indicators were monitored.
RESULTS: Baseline characteristics were comparable between the two groups (p > 0.05). While no significant difference in neurotoxicity grading was observed at 4 weeks (p > 0.05), the observation group demonstrated significantly better NCI-CTCAE grades than the control group at 8 weeks (p < 0.05). NCV assessments revealed that motor and sensory NCVs of the median and common peroneal nerves in the observation group were significantly improved compared to both baseline levels and the control group at 4 and 8 weeks (p < 0.05). After 8 weeks, the overall clinical efficacy rate was significantly higher in the observation group (89.47%) than in the control group (67.97%) (p < 0.05). QoL scores across all functional domains (physical, role, cognitive, emotional, and social) were significantly better in the observation group compared to the control group at 8 weeks (p < 0.05). Hematological and liver/kidney function parameters remained within normal ranges and showed no significant intergroup differences post-treatment (p > 0.05).
CONCLUSION: The combination of sodium ferulate and methylcobalamin is superior to methylcobalamin monotherapy in alleviating the severity of neurotoxicity, improving nerve conduction function, enhancing clinical efficacy, and promoting quality of life in CRC patients with OIPN, with a comparable safety profile. It represents a promising clinical treatment option for OIPN.
METHODS: In this retrospective cohort study, 280 CRC patients diagnosed with OIPN following oxaliplatin-based chemotherapy at Qianxi People's Hospital between January 2020 and December 2024 were enrolled. Based on treatment regimen, patients were assigned to an observation group (sodium ferulate combined with methylcobalamin, n = 152) or a control group (methylcobalamin alone, n = 128). All patients received basic nursing care. Treatment duration was 8 weeks for both groups. Outcomes compared between groups included National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) neurotoxicity grading, nerve conduction velocity (NCV), and quality of life (QoL) scores assessed before treatment, at 4 weeks, and at 8 weeks post-treatment. Clinical efficacy was evaluated after 8 weeks, and changes in hematological parameters and liver/kidney function indicators were monitored.
RESULTS: Baseline characteristics were comparable between the two groups (p > 0.05). While no significant difference in neurotoxicity grading was observed at 4 weeks (p > 0.05), the observation group demonstrated significantly better NCI-CTCAE grades than the control group at 8 weeks (p < 0.05). NCV assessments revealed that motor and sensory NCVs of the median and common peroneal nerves in the observation group were significantly improved compared to both baseline levels and the control group at 4 and 8 weeks (p < 0.05). After 8 weeks, the overall clinical efficacy rate was significantly higher in the observation group (89.47%) than in the control group (67.97%) (p < 0.05). QoL scores across all functional domains (physical, role, cognitive, emotional, and social) were significantly better in the observation group compared to the control group at 8 weeks (p < 0.05). Hematological and liver/kidney function parameters remained within normal ranges and showed no significant intergroup differences post-treatment (p > 0.05).
CONCLUSION: The combination of sodium ferulate and methylcobalamin is superior to methylcobalamin monotherapy in alleviating the severity of neurotoxicity, improving nerve conduction function, enhancing clinical efficacy, and promoting quality of life in CRC patients with OIPN, with a comparable safety profile. It represents a promising clinical treatment option for OIPN.